Pfizer expects fewer people needed for Lyme disease vaccine trial
Pfizer said it expects fewer people will be needed to complete its Phase III trial of Valneva’s Lyme disease vaccine candidate than originally thought. The
Pfizer said it expects fewer people will be needed to complete its Phase III trial of Valneva’s Lyme disease vaccine candidate than originally thought. The
One out of 100 people will experience a psychotic episode in their lifetime, and these usually appear in late adolescence or early adulthood.
Researchers examined the effect of Bacillus Calmette-Guérin (BCG) vaccination on attenuating herpes labialis (cold sore) recurrences.